Efficacy and Safety of Intravenous Immunoglobulin in Paediatric Patients with Primary Immunodeficiency Diseases

Abstract

This is a longitudinal study to evaluate the efficacy and safety of regular intravenous immunoglobulins (IVIG) among patients with primary immunodeficiency diseases The study included 40 patients with primary immunodeficiency following-up regularly in the Pediatric Allergy , Immunology and Rheumatology Unit, Children’s Hospital, Ain-Shams University including predominantly antibody deficiency (PAD) and combined immunodeficiency (CID) on regular IVIG therapy in a dose (0.5gm/kg every 4 weeks) .Those patient was followed For 12 months. Our studied patients had a median of 6 infections/year (IQR: 4-8) before IVIG and 3 infections/year (IQR: 3-4.5) after IVIG (P<0.001) This proves efficacy of in reducing the rate of infections before and after IVIG treatment for 1 year with a highly statistical significant difference (p=0.01) Another evidence of IVIG efficacy is the reduction in the hospitalization rate in patients with PAD with significant statistical difference (P=0.02).